We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > ARIKAYCE

News List

Insmed Initiates ARIKAYCE Trial for MAC Lung Disease americanpharmaceuticalreview
January 11, 2021
Insmed announced the first patient was dosed in the frontline clinical trial program of ARIKAYCE® (amikacin liposome inhalation suspension) in patients with nontuberculous mycobacterial (NTM) lung disease caused by Mycobacterium avium complex (MAC).
EC Grants Authorization for ARIKAYCE Liposomal Nebulizer Dispersion for NTM Lung Infections americanpharmaceuticalreview
November 06, 2020
Insmed Incorporated announced the European Commission (EC) has granted marketing authorization for ARIKAYCE® Liposomal 590 mg Nebulizer Dispersion for the treatment of nontuberculous mycobacterial (NTM) lung infections caused by Mycobacterium avium ...